Redeye returns with a reinforced view on the longer-term commercial outlooks for IRRAS, given its strengthened foundation for future growth and increased initial focus on clinical validation. We have long had a positive take on its sales prospects, though having been affected by external drawdowns and the Coronavirus, this has been held back. Yet, its operational achievements still bode for an attractive high sales growth case ahead.